Related Experiment Videos
Moderate anticonvulsant action of baclofen does not change during development
H Kubová1, R Haugvicová, P Mares
1Institute of Physiology, Academy of Sciences, Czech Republic, Prague.
Biology of the Neonate
|January 1, 1996
Summary
Baclofen, a GABAB receptor agonist, showed moderate anticonvulsant effects against tonic seizures in rats. Its efficacy varied by seizure type and administration route, but not significantly with age.
Area of Science:
- Neuroscience
- Pharmacology
- Developmental Biology
Background:
- Baclofen is a GABAB receptor agonist.
- Pentylenetetrazol (PTZ) is commonly used to induce seizures in animal models.
- Understanding drug efficacy across developmental stages is crucial.
Purpose of the Study:
- To investigate the anticonvulsant potential of baclofen.
- To assess baclofen's effects on different seizure types (clonic and tonic-clonic).
- To evaluate baclofen's efficacy in rats of varying ages (7, 12, 18, and 25 days old).
Main Methods:
- Baclofen was administered intraperitoneally and subcutaneously to adult rats and rat pups.
- Seizures were induced using pentylenetetrazol (PTZ).
- Effects were evaluated based on seizure type, latency, and suppression of seizure phases.
Main Results:
- Subcutaneous baclofen moderately suppressed the tonic phase of generalized tonic-clonic seizures in all age groups.
- Baclofen did not affect minimal, clonic seizures.
- Intraperitoneal administration showed limited efficacy, with only a 12-mg/kg dose prolonging seizure latency in 12-day-old rats.
Conclusions:
- Baclofen's anticonvulsant action is dependent on the seizure model.
- Baclofen's efficacy against PTZ-induced seizures does not significantly change during postnatal development in rats.
- The route of administration and seizure type influence baclofen's effectiveness.